MagnetisMM-6

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 13, 2021 → Oct 12, 2026

Cited window

Feb 19, 2023 → Oct 12, 2026

Retrieved

Oct 24, 2026

Title

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Registry

NCT05623020

Study IDs

C1071006 · MAGNETISMM-6 (Alias Study Number) · 2024-514139-50-00 (CTIS (EU))

Sponsor

Pfizer

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

1,060 estimated

Start

2022-11-10 actual

Primary completion

2030-10-18 estimated

Primary endpoint

Part 1 Dose Limiting Toxicity

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 6 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –422 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition do not represent all HCPs or establish how common any opinion is. Reposts, organizational reporting and multiple media versions of the same discussion should not be counted as independent clinician agreement.
• –Relevant discussions that do not name the trial or use different terminology may be missing. One social discussion was inaccessible, and portions of several long recordings were not fully evaluated, so less prominent views may be absent.
• –Some recordings do not identify who voiced the relevant passage. Those views remain unnamed even when a program lists recognizable participants.
• –No full protocol or trial-results publication was available to reconcile the reported efficacy, safety, denominator and follow-up differences. Reported numbers are what the cited speakers or organizations said.
• –Earlier descriptions of a DRd comparator and later descriptions of DVRd are preserved in their own temporal context. Publication dates do not establish the date of a design decision or a change in an individual's opinion.
• –Favorable response, tolerability and biological-rationale comments do not establish randomized comparative benefit, validated MRD-guided stopping or a preferred finite treatment duration.
• –Class-wide experience, individual patient experience, other frontline regimen choices and sequencing hypotheses are distinguished from observations made specifically in MagnetisMM-6. Proposed alternatives to current induction remain research questions, not established treatment replacements.
• –Raffaele Di Giacomo's clinical role is not stated in the sources reviewed; the author's questions should not be treated as an additional confirmed HCP endorsement.

How reports are built and checked: Methods.

Last checked for new commentary Oct 24, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.